Abstract. Hepatitis B infection is still a global concern progressing as acute-chronic hepatitis, severe liver failure, and death. The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids. Pregnant women, adolescents, and all adults at high risk of chronic infection are recommended to be ...
New Approaches to Chronic Hepatitis B
Preclinical Research Approaches. ... Current levels of diagnosis and treatment of hepatitis B are inadequate. Approximately 10% of people living with hepatitis B knew their status in 2019. Of this ...
Recent Advances in Hepatitis B Treatment
Abstract. Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos (t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells.
Hepatitis B Treatment: What We Know Now and What Remains to Be
Abstract. Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos (t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular ...
New Therapeutics for Hepatitis B: The Road to Cure
Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable tr …
The scientific basis of combination therapy for chronic hepatitis B
Functional cure of chronic hepatitis B (CHB) — or hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy — is now the goal of treatment, but is rarely achieved with current therapy.
Hepatitis B
Hepatitis B is inflammation of the liver in hominoidea, including humans, caused by the hepatitis B virus. The virus is transmitted by parenteral exposure, such as by exposure to infectious blood ...
NIH strategic plan details pathway to achieving Hepatitis B cure
To effectively address the global public health challenge posed by HBV, a curative treatment will need to complement better approaches to screening, follow-up care, and vaccination coverage. The Strategic Plan for Trans-NIH Research to Cure Hepatitis B focuses on three key research areas. The first priority calls for a better understanding of ...
NIH Updates Hepatitis B Strategic Research Plan
The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care. The revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology.
Closing in on a cure for hepatitis B
For Thomas Tu, eliminating hepatitis B is a deeply personal goal. Tu, a molecular virologist at the Westmead Institute for Medical Research in Sydney, Australia, learnt he had chronic hepatitis B ...
A global scientific strategy to cure hepatitis B
Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key ...
Hepatitis B virus
Chronic hepatitis B (CHB) remains a major global health problem affecting more than 240 million people with high liver-related morbidity and mortality worldwide. This snapshot summarizes available HBV therapeutic strategies and highlights their corresponding stages of development from late preclinical to various clinical phases, which are indicated by different colors.
Review article: hepatitis B-current and emerging therapies
Background: The hepatitis B virus (HBV) affects an estimated 290 million individuals worldwide and is responsible for approximately 900 000 deaths annually, mostly from complications of cirrhosis and hepatocellular carcinoma. Although current treatment is effective at preventing complications of chronic hepatitis B, it is not curative, and often must be administered long term.
Optimizing treatment regimens for adults with chronic hepatitis B
The NIDDK-funded HBRN conducted clinical trials of treatment approaches for chronic hepatitis B in a study population that was primarily men, women, and children of Asian descent. Though the Network studies concluded in 2022, data analysis and publication of results has continued, with study samples available for additional research through the ...
PDF The NIH Hepatitis B Cure Strategic Plan Working Group
Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. However, there is no intervention that cures HBV infection. ... Research to Cure Hepatitis B, which detailed NIH efforts to advance innovative hepatitis B research and improve strategies for vaccination, screening, and follow-up to ...
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
In the United States, by CDC estimates, only one-third of HBV-infected patients or less are aware of their infection. Some reasons for these low rates of surveillance, diagnosis, and treatment include the asymptomatic nature of chronic hepatitis B until the very late stages, a lack of curative therapy with a finite treatment duration, a complex ...
Advances in treatment and prevention of hepatitis B
Further research is needed to determine specific cutoff values of HBcrAg to determine clinical outcomes and determine the role of HBV RNA in occult hepatitis B infection, ... HEPATITIS B TREATMENT . Per the 2018 updates to the AASLD guidelines, patients with CHB (Persistence of HBsAg > six months) should be considered for treatment if the ALT ...
Hepatitis B
Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term). Hepatitis B can cause a chronic infection and puts people at high risk of death from cirrhosis and liver cancer. It can spread through contact with infected body fluids like blood, saliva, vaginal ...
A roadmap for serum biomarkers for hepatitis B virus: current status
Treatment results in hepatitis B surface antigen (HBsAg) loss (also known as functional cure) ... More research is required to determine the usefulness of quantitative anti-HBs, anti-HBe and anti ...
Tackling hepatitis B Virus with CRISPR/Cas9: advances ...
Hepatitis B virus (HBV) infection remains a significant global health challenge, with chronic HBV leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Current treatments often fail to eradicate the virus, highlighting the need for innovative therapeutic strategies. The CRISPR/Cas9 system has emerged as a dynamic tool for precise genome editing and presents a ...
Improving integrated perinatal care for women with hepatitis B in China
Huishu Liu and colleagues argue that integrated care for women with hepatitis B in China needs improving, including better severity stratification, comprehensive counselling and education, seamless multidisciplinary care, and better referral ### Key messages Hepatitis B virus infection is a public health issue globally, with a worldwide prevalence of nearly 3.8% and 1.5 million new infections ...
Hepatitis B vaccination coverage and associated factors among nurses
Hepatitis B virus (HBV) is a viral infection that causes HBV disease, which infects the liver and can lead to chronic liver diseases like cirrhosis and hepatocellular carcinoma [].HBV is a major public health problem worldwide [].The World Health Organization's (WHO) global hepatitis report for 2024 shows that viral hepatitis caused 1.3 million deaths in 2022, and hepatitis B caused 83% of ...
Review of Current and Potential Treatments for Chronic Hepatitis B
Hepatitis B virus (HBV) infection is a leading cause of chronic liver disease, affecting more than 290 million people worldwide. 1 Annually, 750,000 people die from complications of chronic HBV infection. 2 Elimination or suppression of HBV reduces the risk of developing chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Current treatments are associated with improved liver ...
The application and functional mechanism of Chinese herbal medicines in
HBV, a hepatotropic DNA virus, can cause chronic and acute Hepatitis B and persistent infection may cause serious complications like cirrhosis, liver cancer, and liver failure. Though nucleos(t)ide analogues (NAs) is the first-line drug for chronic hepatitis B (CHB), they still have several drawbacks such as drug resistance, and low-level viremia.
Global burden of hepatitis B virus: current status, missed
Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also include ...
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Though further research is indicated, POC tests for HBsAg may prove to be accurate, rapid, and less expensive choices than laboratory serological screening for HBV in the field. ... Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 51:830-839. doi: 10.1007 ...
New insights into stiff-person syndrome, advancing diagnosis and treatment
Shedding light on the rare neurological disorder 'stiff-person syndrome,' review explores the complex role of GAD antibodies and cutting-edge therapies, paving the way for better patient care.
Hepatitis B
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously. Patients can present with acute ...
The hepatitis C virus envelope protein complex is a dimer of
Fifty-eight million individuals worldwide are affected by chronic hepatitis C virus (HCV) infection, a primary driver of liver cancer for which no vaccine is available 1.The HCV envelope proteins ...
COMMENTS
Abstract. Hepatitis B infection is still a global concern progressing as acute-chronic hepatitis, severe liver failure, and death. The infection is most widely transmitted from the infected mother to a child, with infected blood and body fluids. Pregnant women, adolescents, and all adults at high risk of chronic infection are recommended to be ...
Preclinical Research Approaches. ... Current levels of diagnosis and treatment of hepatitis B are inadequate. Approximately 10% of people living with hepatitis B knew their status in 2019. Of this ...
Abstract. Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos (t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells.
Abstract. Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, interferons (IFNs) and nucleos (t)ide analogues (NAs), have been approved. These treatments are effective in suppressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular ...
Chronic hepatitis B virus (HBV) infection impacts an estimated 257-291 million people globally. The current approach to treatment for chronic HBV infection is complex, reflecting a risk:benefit approach driven by the lack of an effective curative regimen. This complexity and the lack of a durable tr …
Functional cure of chronic hepatitis B (CHB) — or hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy — is now the goal of treatment, but is rarely achieved with current therapy.
Hepatitis B is inflammation of the liver in hominoidea, including humans, caused by the hepatitis B virus. The virus is transmitted by parenteral exposure, such as by exposure to infectious blood ...
To effectively address the global public health challenge posed by HBV, a curative treatment will need to complement better approaches to screening, follow-up care, and vaccination coverage. The Strategic Plan for Trans-NIH Research to Cure Hepatitis B focuses on three key research areas. The first priority calls for a better understanding of ...
The National Institutes of Health has updated its Strategic Plan for NIH Research to Cure Hepatitis B, a roadmap for ending the hepatitis B epidemic, focused on developing a cure as well as improved strategies for vaccination, screening and follow-up care. The revised plan incorporates lessons from the COVID-19 pandemic and recent advances in technology.
For Thomas Tu, eliminating hepatitis B is a deeply personal goal. Tu, a molecular virologist at the Westmead Institute for Medical Research in Sydney, Australia, learnt he had chronic hepatitis B ...
Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE-HBV) is a coalition of experts dedicated to accelerating the discovery of a cure for chronic hepatitis B. Following extensive consultation with more than 50 scientists from across the globe, as well as key ...
Chronic hepatitis B (CHB) remains a major global health problem affecting more than 240 million people with high liver-related morbidity and mortality worldwide. This snapshot summarizes available HBV therapeutic strategies and highlights their corresponding stages of development from late preclinical to various clinical phases, which are indicated by different colors.
Background: The hepatitis B virus (HBV) affects an estimated 290 million individuals worldwide and is responsible for approximately 900 000 deaths annually, mostly from complications of cirrhosis and hepatocellular carcinoma. Although current treatment is effective at preventing complications of chronic hepatitis B, it is not curative, and often must be administered long term.
The NIDDK-funded HBRN conducted clinical trials of treatment approaches for chronic hepatitis B in a study population that was primarily men, women, and children of Asian descent. Though the Network studies concluded in 2022, data analysis and publication of results has continued, with study samples available for additional research through the ...
Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. However, there is no intervention that cures HBV infection. ... Research to Cure Hepatitis B, which detailed NIH efforts to advance innovative hepatitis B research and improve strategies for vaccination, screening, and follow-up to ...
In the United States, by CDC estimates, only one-third of HBV-infected patients or less are aware of their infection. Some reasons for these low rates of surveillance, diagnosis, and treatment include the asymptomatic nature of chronic hepatitis B until the very late stages, a lack of curative therapy with a finite treatment duration, a complex ...
Further research is needed to determine specific cutoff values of HBcrAg to determine clinical outcomes and determine the role of HBV RNA in occult hepatitis B infection, ... HEPATITIS B TREATMENT . Per the 2018 updates to the AASLD guidelines, patients with CHB (Persistence of HBsAg > six months) should be considered for treatment if the ALT ...
Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term). Hepatitis B can cause a chronic infection and puts people at high risk of death from cirrhosis and liver cancer. It can spread through contact with infected body fluids like blood, saliva, vaginal ...
Treatment results in hepatitis B surface antigen (HBsAg) loss (also known as functional cure) ... More research is required to determine the usefulness of quantitative anti-HBs, anti-HBe and anti ...
Hepatitis B virus (HBV) infection remains a significant global health challenge, with chronic HBV leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Current treatments often fail to eradicate the virus, highlighting the need for innovative therapeutic strategies. The CRISPR/Cas9 system has emerged as a dynamic tool for precise genome editing and presents a ...
Huishu Liu and colleagues argue that integrated care for women with hepatitis B in China needs improving, including better severity stratification, comprehensive counselling and education, seamless multidisciplinary care, and better referral ### Key messages Hepatitis B virus infection is a public health issue globally, with a worldwide prevalence of nearly 3.8% and 1.5 million new infections ...
Hepatitis B virus (HBV) is a viral infection that causes HBV disease, which infects the liver and can lead to chronic liver diseases like cirrhosis and hepatocellular carcinoma [].HBV is a major public health problem worldwide [].The World Health Organization's (WHO) global hepatitis report for 2024 shows that viral hepatitis caused 1.3 million deaths in 2022, and hepatitis B caused 83% of ...
Hepatitis B virus (HBV) infection is a leading cause of chronic liver disease, affecting more than 290 million people worldwide. 1 Annually, 750,000 people die from complications of chronic HBV infection. 2 Elimination or suppression of HBV reduces the risk of developing chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC). Current treatments are associated with improved liver ...
HBV, a hepatotropic DNA virus, can cause chronic and acute Hepatitis B and persistent infection may cause serious complications like cirrhosis, liver cancer, and liver failure. Though nucleos(t)ide analogues (NAs) is the first-line drug for chronic hepatitis B (CHB), they still have several drawbacks such as drug resistance, and low-level viremia.
Chronic hepatitis B virus (HBV) infection affects about 296 million people worldwide and is the leading aetiology of cirrhosis and liver cancer globally. Major medical complications also include ...
Though further research is indicated, POC tests for HBsAg may prove to be accurate, rapid, and less expensive choices than laboratory serological screening for HBV in the field. ... Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 51:830-839. doi: 10.1007 ...
Shedding light on the rare neurological disorder 'stiff-person syndrome,' review explores the complex role of GAD antibodies and cutting-edge therapies, paving the way for better patient care.
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously. Patients can present with acute ...
Fifty-eight million individuals worldwide are affected by chronic hepatitis C virus (HCV) infection, a primary driver of liver cancer for which no vaccine is available 1.The HCV envelope proteins ...